1 / 12

Multidisciplinary Approach for Mood Disorders & Alzheimer's

Introduction to research paradigms, behavioral experiments, molecule selection, models, timelines, and technical platforms. Comprehensive study on mood disorders and Alzheimer's.

gsanon
Download Presentation

Multidisciplinary Approach for Mood Disorders & Alzheimer's

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Day 1 1-2:30pm - MDWP1 • Introduction (10 min): What we said we would do in the application • Why the two paradigms (LPS and BCG) were chosen • What we hope the behavioural experiments will show • Process for choosing molecules • What we have actually done and what next? • LPS model – Diana • BCG model – Jason/Niels • Additional info (Jon)?

  2. Workplansand timeline (from interview slides April 2014) Complementary expertise and assets - academic strengths in translational research and industrial strengths in drug development – combined in a multidisciplinary consortium Part 2 - Mood Disorders Therapeutic PoC trial of an anti-inflammatory in immuno-stratified TRD patients. Part 1 - Mood Disorders MD WP1 – Inflammatory preclinical models MD WP2 – “Immunomarkers” in Treatment Resistant Depression (TRD) Milestone Review Part 2 - Alzheimer’s Disease Experimental Medicine study of an anti-inflammatory in early AD. Part 1 - Alzheimer’s Disease AD WP1 – Clinical Informatics AD WP2 – Animal models AD WP3 – Hypothesis-driven immune system biomarkers • Technical Platforms: • TP1 - Peripheral cytometry, cell sorting, transcriptomics • TP2 – Proteomics in blood and CSF • TP3 – PET imaging of brain inflammation • TP4 – MRI of brain structure and function 0 1 2 3 4 5 Years

  3. Mood Disorder Workplans(from interview slides April 2014) MD WP2 Peripheral Immunomarker validation in TRD MD WP1 Inflammatory models in rodents • Biomarkers • immunophenotyping • Gene expression • Behaviour • CSF • sMRI, fMRI • Microglia studies • Autoradiography • Histology • Site of drug action • central vsperipheral • Selection of drugs • Effects on mood/inflammation • Primary Cohort • 80 TRD patients and 80 controls • Clinical and cognitive profile • Immunophenoptype • sMRI and fMRI • Secondary Cohort • 20 TRD patients and 20 controls • TSPO PET imaging • CSF sampling Immunopsychiatry May 2014-16 • Output to enable Part 2 clinical therapeutic PoC trial: • Understand the links between peripheral and CNS inflammation, brain function, and behaviour • Identify appropriate biomarkers to choose the right patients • Determine most appropriate drug s for clinical evaluation

  4. Objectives of MD Workpackages • Understand the links between peripheral and CNS inflammation, brain function, and behaviour • Identify appropriate biomarkers to choose the right patients • Determine most appropriate drugs for clinical evaluation

  5. MDWP1 – Why these 2 preclinical models? From the application (technical appendix): • We will use two inflammatory models of depression-like behaviour in animals …….These studies will be designed to achieve three objectives: • To improve understanding of mechanistic links between peripheral inflammatory challenges, central inflammatory states, brain function, and depressive behaviours. • To test a range of pharmacological tool compounds, with different MOA & different levels of brain penetration, for efficacy on behavioural endpoints and candidate biomarkers • To cross-validate neuroimaging markers of central inflammatory states by immunohistological and transcriptomic measures of brain tissue (LPS challenge studies only).

  6. MDWP1 – from application • Assumptions: • LPS was the “work horse” to translate/bridge inflammatory biomarkers, more rapidly screen drugs for “pharmacodynamic” effects in CNS etc • CNS vs systemic site of action? • BCG model – evaluate link between drug effects upon inflammation and “mood”

  7. MDWP1 - Process for choosing molecules • A lot of calls!! • Will tally up for SAB etc • Discussions followed these criteria: • Likelihood of a clinical asset for Stage 2? • Appropriate tool molecule for rodent studies (and data package to allow exp design). • Not necessarily the clinical asset • Appropriate scientific rationale • Publishable

  8. Compounds from Janssen & Lundbeck# (from interview slides April 2014) *existing clinical stage assets, other reviewed as they progress to clinical stage; #Subject to prior internal company diligence

  9. Targeting P2X7 and inflammation in mood (from interview slides April 2014) Anhedonia ? ATP Proinflammatory Cytokines Chronic Stress Despair Clinical Depression P2X7 Neurogenesis • P2X7 is an ATP gated ion channel that mediates IL-1brelease • Located on monocytic-lineage cells, including microglia and astrocyes • Plasma IL-1b is elevated in in animal stress models and in MDD and Bipolar patients (Jones & Thomsen, 2013) • P2X7 antagonists may have an antidepressant effect • “Gain of function” polymorphism assoc’d with mood disorders (Halmai et al., 2013) • P2X7 KO mice are stress resilient • P2X7 antagonist have antidepressant activity in preclinical models • Opportunity to fully characterise P2X7 antagonist in preclinical models of CNS inflammation and potentially in depressed patients

  10. Backups

  11. MDWP1 – detailed questions (Application Appendix) • Do anti-inflammatory drugs alleviate depressive-like behaviours in rodent models indicative of potential antidepressant efficacy in a sub-group of depressed patients with peripheral inflammation? • Can we attenuate depressive symptoms by administration of anti-cytokine antibodies that reduce peripheral concentrations of pro-inflammatory cytokines but do not cross the BBB? • Is there additional anti-depressant benefit from administration of molecules that can cross the BBB and engage targets in the brain? This question could be tested, for example, by a comparison of drugs that engage the same target but have different degrees of brain penetrance (e.g., peripheral vs nasal anti-TNF centyrin).. • Do drugs that putatively target microglial activation (e.g., P2X7 inhibitors such as JNJ-47965567 or Lu AF27139; or a KCNN4 antagonist such as Lu AF55813) have effects on imaging and CSF markers that are compatible with that mechanism of action? Do microglial-targeting drugs confer additional anti-depressant benefits? • Can we demonstrate that drugs such as chemokine antagonists that block extravasation of activated immune cells across the BBB from the periphery have anti-depressant effects, perhaps especially in the later stages of depressive response to BCG challenge?

  12. MDWP1 – from application

More Related